PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
5.51%
Revenue growth 1.25-1.5x 3088.T's 3.69%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
-2.33%
Negative gross profit growth while 3088.T is at 4.04%. Joel Greenblatt would examine cost competitiveness or demand decline.
-4.92%
Negative EBIT growth while 3088.T is at 38.28%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-5.57%
Negative operating income growth while 3088.T is at 41.55%. Joel Greenblatt would press for urgent turnaround measures.
-5.25%
Negative net income growth while 3088.T stands at 41.57%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-5.25%
Negative EPS growth while 3088.T is at 38.06%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-5.25%
Negative diluted EPS growth while 3088.T is at 38.06%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.00%
Share reduction while 3088.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3088.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.89%
10Y revenue/share CAGR under 50% of 3088.T's 21.23%. Michael Burry would suspect a lasting competitive disadvantage.
2.89%
5Y revenue/share CAGR under 50% of 3088.T's 21.23%. Michael Burry would suspect a significant competitive gap or product weakness.
-21.33%
Negative 3Y CAGR while 3088.T stands at 13.57%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
100.00%
Positive long-term OCF/share growth while 3088.T is negative. John Neff would see a structural advantage in sustained cash generation.
100.00%
Positive OCF/share growth while 3088.T is negative. John Neff might see a comparative advantage in operational cash viability.
100.00%
Positive 3Y OCF/share CAGR while 3088.T is negative. John Neff might see a big short-term edge in operational efficiency.
79.77%
Similar net income/share CAGR to 3088.T's 74.36%. Walter Schloss would see parallel tailwinds or expansions for both firms.
79.77%
5Y net income/share CAGR similar to 3088.T's 74.36%. Walter Schloss might see both on parallel mid-term trajectories.
-8.48%
Negative 3Y CAGR while 3088.T is 92.49%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
37.97%
10Y equity/share CAGR at 50-75% of 3088.T's 55.41%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
37.97%
5Y equity/share CAGR at 50-75% of 3088.T's 55.41%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
-7.15%
Negative 3Y equity/share growth while 3088.T is at 39.16%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.88%
Firm’s AR is declining while 3088.T shows 22.39%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
2.67%
Inventory shrinking or stable vs. 3088.T's 11.38%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
2.78%
Asset growth at 50-75% of 3088.T's 5.56%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
3.84%
BV/share growth above 1.5x 3088.T's 1.27%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-13.52%
We’re deleveraging while 3088.T stands at 1672.88%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-1.33%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.